التفاصيل البيبلوغرافية
| العنوان: |
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab |
| المؤلفون: |
Toboso, Inmaculada, Tejeda-Velarde, Amalia, Alvarez-Lafuente, Roberto, Arroyo, Rafael, Hegen, Harald, Deisenhammer, Florian, Sainz de la Maza, Susana, Alvarez-Cermeño, José C., Izquierdo, Guillermo, Paramo, Dolores, Oliva, Pedro, Casanova, Bonaventura, Agüera-Morales, Eduardo, Franciotta, Diego, Gastaldi, Matteo, Fernández, Oscar, Urbaneja, Patricia, Garcia-Dominguez, José M., Romero, Fernando, Laroni, Alicia, Uccelli, Antonio, Perez-Sempere, Angel, Saiz, Albert, Blanco, Yolanda, Galimberti, Daniela, Scarpini, Elio, Espejo, Carmen, Montalban, Xavier, Rasche, Ludwig, Paul, Friedemann, González, Inés, Ãlvarez, Elena, Ramo-Tello, Cristina, Caminero, Ana B., Aladro, Yolanda, Calles, Carmen, EguÃa, Pablo, Belenguer-Benavides, Antonio, Ramió-Torrentà , LluÃs, Quintana, Ester, MartÃnez-RodrÃguez, José E., Oterino, AgustÃn, López de Silanes, Carlos, Casanova, Luis I., Landete Pascual, Lamberto, Frederiksen, Jette, Bsteh, Gabriel, Mulero, P., Comabella, Manuel, Hernández, Miguel A., Espiño, Mercedes, Prieto, José M., Pérez, Domingo, Otano, MarÃa, Padilla, Francisco, GarcÃa-Merino, Juan A., Navarro Cantó, Laura, Muriel, Alfonso, Frossard, Lucienne Costa, Villar, Luisa M., Universitat Autònoma de Barcelona |
| سنة النشر: |
2020 |
| المجموعة: |
Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB |
| مصطلحات موضوعية: |
Multiple sclerosis, Demyelinating diseases, Biomarkers, Natalizumab, Progressive multifocal leucoencephalopathy, Disease modifying treatments |
| الوصف: |
Overview: We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36 University Hospitals in Europe. We performed the study in 1,307 multiple sclerosis patients (70.8% anti-John Cunninghan virus positive antibodies) treated with natalizumab for a median time of 3.28 years. Epidemiological, clinical, and laboratory variables were collected. Lipid-specific IgM oligoclonal band status was available in 277 patients. Factors associated with progressive multifocal leucoencephalopathy onset were explored by uni- and multivariate logistic regression. Results: Thirty-five patients developed progressive multifocal leucoencephalopathy. The multivariate analysis identified anti-John Cunninghan virus antibody indices and relapse rate as the best predictors for the onset of this serious opportunistic infection in the whole cohort. They allowed to stratify progressive multifocal leucoencephalopathy risk before natalizumab initiation in individual patients [area under the curve (AUC) = 0.85]. The risk ranged from <1/3,300 in patients with anti-John Cunninghan virus antibody indices <0.9 and relapse rate >0.5, to 1/50 in the opposite case. In patients with lipid-specific IgM oligoclonal bands assessment, age at natalizumab onset, anti-John Cunninghan virus antibody indices, and lipid-specific IgM oligoclonal band status predicted progressive multifocal leucoencephalopathy risk (AUC = 0.92). The absence of lipid-specific IgM oligoclonal bands was the best individual predictor (OR = 40.94). The individual risk ranged from <1/10,000 in patients younger than 45 years at natalizumab initiation, who showed anti John Cunningham virus antibody indices <0.9 and lipid-specific IgM oligoclonal bands to 1/33 in the opposite case. Conclusions: In a perspective of personalized medicine, disease activity, anti-lipid specific IgM oligoclonal bands, anti Jonh Cunninghan virus antibody ... |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
Instituto de Salud Carlos III PI15/00513; Instituto de Salud Carlos III PI18/00572; Instituto de Salud Carlos III RD17/0015; Frontiers in neurology; Vol. 11 (december 2020); https://ddd.uab.cat/record/252286Test; urn:10.3389/fneur.2020.579438; urn:oai:ddd.uab.cat:252286; urn:pmcid:PMC7780851; urn:pmc-uid:7780851; urn:pmid:33408681; urn:oai:pubmedcentral.nih.gov:7780851; urn:scopus_id:85098937296; urn:oai:egreta.uab.cat:publications/7877feed-46ec-4dbd-bd4d-5104df688a86 |
| الإتاحة: |
https://ddd.uab.cat/record/252286Test |
| حقوق: |
open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.80636551 |
| قاعدة البيانات: |
BASE |
